Mon-Fri 9:00-18:00 CET+39 095 7211344info@vitasanlabs.com

Family · Pharmaceutical analytical standards

Tafamidis

A transthyretin stabiliser: in ATTR amyloidosis this protein falls apart and forms deposits in the nerves and heart. Approved in Europe in 2011 for polyneuropathy and in the United States in 2019 for cardiomyopathy. This family brings together the active ingredient, metabolites, labelled standards and other impurities.

Did you know?It was invented at Scripps Research in La Jolla, California, by chemists Jeffery Kelly and Evan Powers: it slots into the protein and holds it together like a molecular staple, stopping it from coming apart.

TafamidisGo to the active ingredient →
TafamidisActive ingredientTafamidisCat. No. P-T006-001CAS 594839-88-0

Need a molecule you cannot find?

Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.